322 related articles for article (PubMed ID: 24065765)
1. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
[TBL] [Abstract][Full Text] [Related]
2. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.
Kats LM; Reschke M; Taulli R; Pozdnyakova O; Burgess K; Bhargava P; Straley K; Karnik R; Meissner A; Small D; Su SM; Yen K; Zhang J; Pandolfi PP
Cell Stem Cell; 2014 Mar; 14(3):329-41. PubMed ID: 24440599
[TBL] [Abstract][Full Text] [Related]
3. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
4. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
6. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
[TBL] [Abstract][Full Text] [Related]
8. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
[TBL] [Abstract][Full Text] [Related]
9. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
[TBL] [Abstract][Full Text] [Related]
10. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
11. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
Sasaki M; Knobbe CB; Munger JC; Lind EF; Brenner D; Brüstle A; Harris IS; Holmes R; Wakeham A; Haight J; You-Ten A; Li WY; Schalm S; Su SM; Virtanen C; Reifenberger G; Ohashi PS; Barber DL; Figueroa ME; Melnick A; Zúñiga-Pflücker JC; Mak TW
Nature; 2012 Aug; 488(7413):656-9. PubMed ID: 22763442
[TBL] [Abstract][Full Text] [Related]
12. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
13. Molecular synergy underlies the co-occurrence patterns and phenotype of
Dovey OM; Cooper JL; Mupo A; Grove CS; Lynn C; Conte N; Andrews RM; Pacharne S; Tzelepis K; Vijayabaskar MS; Green P; Rad R; Arends M; Wright P; Yusa K; Bradley A; Varela I; Vassiliou GS
Blood; 2017 Oct; 130(17):1911-1922. PubMed ID: 28835438
[No Abstract] [Full Text] [Related]
14. The role of IDH mutations in acute myeloid leukemia.
Montalban-Bravo G; DiNardo CD
Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066
[TBL] [Abstract][Full Text] [Related]
15. (R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Gunn K; Myllykoski M; Cao JZ; Ahmed M; Huang B; Rouaisnel B; Diplas BH; Levitt MM; Looper R; Doench JG; Ligon KL; Kornblum HI; McBrayer SK; Yan H; Duy C; Godley LA; Koivunen P; Losman JA
Cancer Discov; 2023 Jun; 13(6):1478-1497. PubMed ID: 36847506
[TBL] [Abstract][Full Text] [Related]
16. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm.
Issa GC; DiNardo CD
Blood Cancer J; 2021 Jun; 11(6):107. PubMed ID: 34083508
[TBL] [Abstract][Full Text] [Related]
18. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.
Chao HY; Jia ZX; Chen T; Lu XZ; Cen L; Xiao R; Jiang NK; Ying JH; Zhou M; Zhang R
Int J Lab Hematol; 2012 Oct; 34(5):502-9. PubMed ID: 22494415
[TBL] [Abstract][Full Text] [Related]
19. Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in
Shih AH; Meydan C; Shank K; Garrett-Bakelman FE; Ward PS; Intlekofer AM; Nazir A; Stein EM; Knapp K; Glass J; Travins J; Straley K; Gliser C; Mason CE; Yen K; Thompson CB; Melnick A; Levine RL
Cancer Discov; 2017 May; 7(5):494-505. PubMed ID: 28193779
[TBL] [Abstract][Full Text] [Related]
20. Isocitrate dehydrogenase mutations in myeloid malignancies.
Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
